05.Jun.2018

Patient enrollment for a phase III study of a drug for seborrheic dermatitis has been completed 1.5 months earlier than initially planned

This is a multicenter, randomized, blind, parallel-group phase III study.

The study aims to evaluate the efficacy, safety and individual tolerance of treatment with a drug in patients with seborrheic dermatitis of the scalp.

More than 250 patients have been enrolled in a study a month and a half prior to the initially set deadline. The total duration of enrollment comprised 4 months.